"Setterwalls Advises Alligator Bioscience on SEK 120 Million Rights Issue and Loan Renegotiation"

"Setterwalls has advised Alligator Bioscience AB on a rights issue of approximately SEK 120 million and the renegotiation of an outstanding loan with Fenja Capital II A/S. This transaction aims to enhance Alligator's financial position and support the ongoing clinical development of its tumor-targeted immuno-oncology antibody drug candidates. Alligator is a clinical-stage biotechnology company based in Lund, Sweden, focused on developing antibody drugs targeting the CD40 receptor."

Setterwalls law firm advised Alligator Bioscience AB in connection with a rights issue of units amounting to approximately SEK 120 million and the renegotiation of the company’s outstanding loan with Fenja Capital II A/S. The transaction aims to strengthen Alligator's financial position and support the ongoing clinical development of its tumor-targeted immuno-oncology antibody drug candidates. Alligator is a clinical-stage biotechnology company focused on developing tumor-directed immuno-oncology antibody drugs targeting the CD40 receptor, and it is listed on Nasdaq Stockholm, with its headquarters located in Medicon Village, Lund, Sweden. The Setterwalls team involved in this transaction included Ola Grahn, Ludwig Isell Lind af Hageby, Rebecca Johnsson, and Ebba Olsson. Their expertise spans various practice areas, including Corporate Law, Equity Capital Markets, and Life Sciences.

"Setterwalls Advises Alligator Bioscience on SEK 120 Million Rights Issue and Loan Renegotiation"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads